Mind Meets Machine: Global

The Neurotechnology of Mental Health.

Anxiety and depression usually get framed as emotional experiences. This episode argues they're also disorders of brain circuitry, and that reframing opens the door to treating them with medical technology, not just therapy and medication.We walk through the full spectrum. Invasive options like Deep Brain Stimulation and Vagus Nerve Stimulation, reserved for severe, treatment-resistant cases. Non-invasive technologies already in clinical use today. And where AI changes the equation entirely.

We also get into what this could look like in practice, from wearable neuromodulation devices to environments that respond automatically to detected stress.

For executives and leaders thinking about where healthtech, AI, and human wellbeing intersect, this episode closes with two questions worth sitting with: what it means to give people tools that regulate their own emotional states, and whether that builds self-awareness or dependence.

REFERENCES:

SUMMARY OF SAFETY AND EFFECTIVENESS DATA

https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024B.pdf

| Depression in adults: treatment and management | Guidance

https://www.nice.org.uk/guidance/ng222/chapter/Recommendations

| Generalised anxiety disorder and panic disorder in adults:

https://www.nice.org.uk/guidance/cg113/chapter/Recommendation

CDRH Humanitarian Device Exemptions

https://www.fda.gov/medical-devices/hde-approvals/listing-cdrh-humanitarian-device-exemptions

Getting a Humanitarian Use Device to Market

https://www.fda.gov/medical-devices/humanitarian-device-exemption/getting-humanitarian-use-device-market

FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder

https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder

https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230024A.pdf

Effect of transcutaneous vagus nerve stimulation with electrical stimulation on generalized anxiety disorder: Study protocol for an assessor-participant blinded, randomized sham-controlled trial - PubMed

https://pubmed.ncbi.nlm.nih.gov/40041000/

Ethics and governance of artificial intelligence for health

https://www.who.int/publications/i/item/9789240029200

Cingulotomy for Intractable Obsessive-compulsive Disorder

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/497081

Potential optimization of focused ultrasound capsulotomy for obsessive compulsive disorder

https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awab232/6305828

Transcranial focused ultrasound of the amygdala modulates fear network activation and connectivity

https://pubmed.ncbi.nlm.nih.gov/38447773/

Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)

https://www.cms.gov/medicare/coverage/evidence/vagus-nerve-stimulation

Transcutaneous vagus nerve stimulation reduces spontaneous but not induced negative thought intrusions in high worriers https://www.sciencedirect.com/science/article/abs/pii/S0301051118302321

Improvement in mood symptoms ​after post-bariatric surgery among people with obesity

https://pubmed.ncbi.nlm.nih.gov/33891377/

Psychiatric and Cognitive Functioning After Metabolic and Bariatric Surgery

https://pubmed.ncbi.nlm.nih.gov/40545266/

Closed-loop neuromodulation in an individual with treatment-resistant depression

https://pubmed.ncbi.nlm.nih.gov/34608328/

NHS Identity Guidelines

https://www.england.nhs.uk/nhsidentity/identity-guidelines/tone-of-voice/

Content design: planning, writing and managing content

https://www.gov.uk/guidance/content-design/writing-for-gov-uk

Centralized or Distributed? The Real AI Org Design Decision

Every growing organization eventually faces the same question: should AI capability live in one central team, or spread across the business units that need it?

In this episode, we walk through how that decision actually plays out as companies scale, and why the "right" answer shifts the moment headcount and complexity grow. We cover the case for a concentrated central team, the operational efficiency and cost trade-offs leadership actually cares about, and the often-overlooked MLOps question: should that function be team-agnostic, or aligned to specific domains?

We also name a dynamic most org charts don't account for: what happens when a business unit gets tired of waiting on a central team and starts solving its own AI problems independently. That's a structural decision with real political consequences inside the company.

From there we turn to healthcare to make a different point: domain experts can't just be looped in for review at the end. If clinicians and frontline staff aren't actively involved in building the model, not just validating it after the fact, the result is a tool that doesn't fit how people actually work. Operationalizing it just creates burnout instead of value.

This conversation is for CEOs, VPs, and directors actively wrestling with how to structure AI and data capability inside their own organizations, closing with a set of questions designed to apply directly to your own org's reality.

[1] Multiple industry sources report AI-powered recruitment tools can reduce time-to-hire by 30% or more. See: DemandSage, “AI Recruitment Statistics 2026,” demandsage.com; McKinsey-cited data reported in JobsPikr, “AI Recruitment in 2025,” jobspikr.com; SHRM, “The Evolving Role of AI in Recruitment and Retention,” shrm.org. Note: figures vary by implementation; the 30% figure represents a commonly cited benchmark, not a guaranteed outcome.

[2] Centers for Disease Control and Prevention (CDC), “Health Workers Face a Mental Health Crisis,” Vital Signs, October 2023. Available at: cdc.gov/vitalsigns/health-worker-mental-health. Reports 46% of health workers felt burned out often or very often in 2022, vs. 32% in 2018.

[3] Mayo Clinic Well-Being Index, 2023–2024 State of Well-Being Report. Reported in HealthLeaders Media, “Where Burnout Rates Are Trending Among Healthcare Professions,” January 2025. Available at: healthleadersmedia.com. Reports 50% of healthcare workers reported burnout in 2023, with nurses at 52% and physicians at 51%.

[4] Wang, Z. et al. (2021). “A Machine Learning Model for Accurate Prediction of Sepsis in ICU Patients.” Frontiers in Medicine, PMC8553999. Reports AUC of 0.91, sensitivity of 87%, specificity of 89% in external validation. See also: Awad, A. et al. (2025). “Artificial Intelligence-Based Predictive Modeling for Early Sepsis Detection: A Systematic Review.” Critical Care Explorations, PMC12685403. Across 52 studies, AUC range of 0.79–0.96.

[5] Verhage, T.L. et al. (2024). “To warrant clinical adoption AI models require a multi-faceted implementation evaluation.” npj Digital Medicine. doi:10.1038/s41746-024-01064-1. Notes fewer than 2% of AI models progress beyond prototyping, and that high statistical accuracy in sepsis ICU tools does not translate to clinical adoption.

[6] Mohr, D.C. et al. (2025). “Adoption of Artificial Intelligence in Healthcare: Survey of Health System Priorities, Successes, and Challenges.” Journal of the American Medical Informatics Association, PMC12202002. Survey of 43 US health systems; clinician alert fatigue and AI tool immaturity identified as leading barriers to adoption, including for sepsis prediction tools.

Middle managers have quietly become one of the most anxious groups in today's workplace, and this episode tackles why head-on. The host opens with a direct question: is AI actually eliminating middle management, or is it exposing a structural problem organizations have ignored for decades?

The episode traces the role's history, from pre-1990s information pipelines, through the IT revolution (which didn't shrink headcount but did raise expectations), to today's AI moment. It names exactly what AI threatens: the synthesis-and-coordination work that defined the job, reports, summaries, status updates. But it argues this exposes what was always irreplaceable: emotional intelligence and conflict resolution, now the core competency for execution.

Using a "weakest link" framing, the host shows how this plays out differently by industry: manufacturing managers freed from traffic-cop duties to become business bridges; consulting leads protected by client relationships but at risk of becoming pure administrators; SaaS managers becoming "AI orchestrators" who decide what to trust rather than doing synthesis themselves; and healthcare/neurotech managers carrying moral accountability AI can't touch.

The back half turns prescriptive: organizations need to redistribute high-value work, formalize neglected secondary relationships, build in time for improvement, and (critically) redefine what managers are measured on, since rewarding throughput just optimizes away the judgment work that matters.

It closes with practical advice for managers (build contextual judgment, become a bridge not a bottleneck, develop your team, get fluent with AI as a collaborator) and three reflective listener questions about where their own value really sits.

References:

• Leavitt, H. J., & Whisler, T. L. (1958). "Management in the 1980s." Harvard Business Review, 36(6), 41–48.
• Dopson, S., & Stewart, R. (1993). "Information Technology, Organisational Restructuring and the Future of Middle Management." New Technology, Work and Employment, 8(1), 10–20.
• Netflix Inc.'s Organizational Structure & Its Strategic Implications — Rancord Society. https://www.rancord.org/netflix-organizational-structure-design-organizational-chart-characteristics
• Spotify Organizational Structure — FourWeekMBA. https://fourweekmba.com/spotify-organizational-structure/
• "Project Oxygen: The 8 Essential Qualities of Effective Managers" — CliffsNotes. https://www.cliffsnotes.com/study-notes/20870159
• "Effective Engineering Managers: The 10 traits that make great managers from Google's Project Oxygen" — Addy Osmani. https://addyo.substack.com/p/effective-engineering-managers
• Goldratt, E. M. — Theory of Constraints (overview). "No Chain Stronger Than Its Weakest Link: Constraints Theory" — IncrementOne. https://www.incrementone.com/perspectives/no-chain-can-ever-be-stronger-than-its-weakest-link-the-theory-of-constraints
• "Why Middle Management will Fall First in the AI Revolution" (Pega survey, 78% of executives) — Chris Hood. https://chrishood.com/why-middle-management-will-fall-first-in-the-ai-revolution/
• "Middle managers are getting laid off—but their role is 'more important than ever'" (Gartner, Oct. 2024 report) — CNBC. https://www.cnbc.com/2025/12/29/middle-managers-are-getting-laid-offbut-their-role-is-more-important-than-ever-says-leadership-expert.html

What happens when psychedelics, neurotechnology, AI, brain-computer interfaces, and even ancient healing practices like Reiki begin converging into a single ecosystem?

In this thought-provoking episode, we explore how neuroscience and artificial intelligence are reshaping our understanding of the human brain and what that means for mental health, healing, performance, and the future of human potential. From Neuralink and brain-computer interfaces to psilocybin therapy, optogenetics, neurofeedback, and emerging cognitive enhancement technologies, we examine the breakthroughs that are moving from research labs into real-world applications.

We also discuss the opportunities and challenges facing practitioners, healthcare innovators, investors, regulators, and everyday people as these technologies evolve. Can AI help personalize mental health treatment? Could neurotechnology validate practices like Reiki? Who should own neural data? And are we prepared for a future where enhancing cognition becomes as common as treating disease?

Whether you're interested in neuroscience, mental health, emerging technology, consciousness, or the future of healthcare, this episode offers a comprehensive look at one of the most important convergences of our time.

Key References & Further Reading:

Boyden ES et al. (2005). Millisecond-timescale,genetically targeted optical control of neural activity. Nature Neuroscience8(9):1263-1268.

MIT Synthetic Neurobiology Group — OptogeneticsProjects: synthneuro.org/projects

Willett FR et al. (2021). High-performancebrain-to-text communication via handwriting. Nature 593:249–254.

Carhart-Harris R et al. (2021). Trial of psilocybinversus escitalopram for depression. NEJM 384:1402-1411.

Hampson RE et al. (2018). Facilitation of memoryencoding in humans via a closed-loop cortical neuroprosthetic. JNE 15(3).

Grand View Research (2024). Neurotechnology MarketSize, Share & Trends Analysis Report.

Sahel JA et al. (2021). Partial recovery of visualfunction in a blind patient after optogenetic therapy. Nature Medicine27:1223-1229.

Iaccarino HF et al. (2016). Gamma frequency entrainmentattenuates amyloid load and modifies microglia. Nature 540:230–235.

"Beyond the Breakthrough Therapy designations forpsilocybin (COMPASS Pathways and USONA Institute, 2018 to 2019) and MDMA-assisted therapy for PTSD" (MAPS, 2017)